<DOC>
	<DOCNO>NCT01622673</DOCNO>
	<brief_summary>This study evaluate : ( 1 ) effect co-administration single dose calcium carbonate antacid magnesium/aluminum hydroxide antacid steady-state plasma pharmacokinetic profile raltegravir human immunodeficiency virus ( HIV ) -infected participant ; ( 2 ) effect stagger dose single dose magnesium/aluminum hydroxide antacid 2 hour 2 hour administration raltegravir steady-state plasma pharmacokinetic profile raltegravir participant . The study determine whether ( 1 ) C12hrs steady-state raltegravir co-administration single dose calcium carbonate antacid decrease clinically meaningful degree compare C12hrs administration raltegravir alone ; whether ( 2 ) C12hrs steady-state raltegravir co-administration single dose magnesium/aluminum hydroxide antacid decrease clinically meaningful degree compare C12hrs administration raltegravir alone .</brief_summary>
	<brief_title>A Pharmacokinetic Study Evaluate Effect Antacids Raltegravir ( MK-0518 ) HIV-Infected Participants ( MK-0518-247 )</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Aluminum hydroxide , magnesium hydroxide , drug combination</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<mesh_term>Antacids</mesh_term>
	<mesh_term>Aluminum hydroxide , magnesium hydroxide , simethicone drug combination</mesh_term>
	<mesh_term>Magnesium Hydroxide</mesh_term>
	<mesh_term>Anti-Ulcer Agents</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<mesh_term>TEMPO</mesh_term>
	<criteria>HIVinfected participant stable raltegravir dose ( 400 mg every 12 hour ) part stable antiretroviral regimen ( ARV ) least 1 month maintain current ARV therapy throughout study Body Mass Index â‰¤32 kg/m^2 Good general health Can current smoker and/or user nicotine nicotinecontaining product , use nicotinecontaining product permit stay clinical research site History gastric bypass surgery Pregnant nursing Mentally legally incapacitate , significant emotional problem , history clinically significant psychiatric disorder ; participant situational depression may enrol discretion investigator . History stroke , chronic seizure , major neurological disorder History clinically significant endocrine , gastrointestinal , cardiovascular , hematological , hepatic , immunological , renal , respiratory , genitourinary abnormality disease ( exclude HIV ) ; participant history uncomplicated kidney stone childhood asthma may enrol discretion investigator . Active neoplastic disease deem unstable progress investigator Currently take rifampin unable refrain use proton pump inhibitor histamine2 ( H2 ) blocker , overthecounter antacid , calcium supplement , multivitamin study Consumes excessive amount alcohol Consumes excessive amount coffee , tea , cola , caffeinated beverage Major surgery blood donation within past 4 week History significant multiple and/or severe allergy anaphylactic reaction significant intolerability prescription nonprescription drug food Regular user illicit drug history drug ( include alcohol ) abuse within past 6 month ; current methadone suboxone use allow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>